Half of renally-cleared rivaroxaban is cleared as unchanged drug and half as inactive metabolites. ‡Potent inhibitors of both CYP3A4 and P-gp include azole antifungals (e.g., ketoconazole ...
Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It ...
The ROCKET AF trial compared rivaroxaban (20 mg/day; 15 mg/day in patients with ... Half of renally-cleared rivaroxaban is cleared as unchanged drug and half as inactive metabolites.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback